| Dr Geoffry De Gennaro Jr, MD | |
|
190 E Bannock St, Boise, ID 83712-6241 | |
| (208) 381-2094 | |
| Not Available |
| Full Name | Dr Geoffry De Gennaro Jr |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 10 Years |
| Location | 190 E Bannock St, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336554740 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 4301105483 (Michigan) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | M-15099 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| St Luke's Nampa Medical Center | Nampa, ID | Hospital |
| St Luke's Wood River Medical Center | Ketchum, ID | Hospital |
| St Luke's Elmore Medical Center | Mountain home, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Boise Radiology Group Pllc | 9638153257 | 53 |
News Archive
Abbott today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle Libre system spend less time in hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) while having improved average glucose levels.
On the occasion of the 2011 Rare Disease Day, EDMA, the European Diagnostic Manufacturers Association, underlines the crucial role the In Vitro Diagnostic industry can play to diagnose rare diseases.
A new Associated Press-GfK poll finds that 71 percent of Americans who have tried to sign up for health coverage, or live with someone who tried, had difficulties with the insurance marketplaces. Meanwhile, some GOP leaders are seeking a policy alternative to replace the overhaul.
The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).
Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.
› Verified 6 days ago
| Entity Name | Boise Radiology Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740216175 PECOS PAC ID: 9638153257 Enrollment ID: O20040614000277 |
News Archive
Abbott today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle Libre system spend less time in hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) while having improved average glucose levels.
On the occasion of the 2011 Rare Disease Day, EDMA, the European Diagnostic Manufacturers Association, underlines the crucial role the In Vitro Diagnostic industry can play to diagnose rare diseases.
A new Associated Press-GfK poll finds that 71 percent of Americans who have tried to sign up for health coverage, or live with someone who tried, had difficulties with the insurance marketplaces. Meanwhile, some GOP leaders are seeking a policy alternative to replace the overhaul.
The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).
Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.
› Verified 6 days ago
| Entity Name | Weiser Valley Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255364030 PECOS PAC ID: 5294704276 Enrollment ID: O20050124000126 |
News Archive
Abbott today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle Libre system spend less time in hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) while having improved average glucose levels.
On the occasion of the 2011 Rare Disease Day, EDMA, the European Diagnostic Manufacturers Association, underlines the crucial role the In Vitro Diagnostic industry can play to diagnose rare diseases.
A new Associated Press-GfK poll finds that 71 percent of Americans who have tried to sign up for health coverage, or live with someone who tried, had difficulties with the insurance marketplaces. Meanwhile, some GOP leaders are seeking a policy alternative to replace the overhaul.
The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).
Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.
› Verified 6 days ago
| Entity Name | North Canyon Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609046671 PECOS PAC ID: 0941371439 Enrollment ID: O20090409000304 |
News Archive
Abbott today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle Libre system spend less time in hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) while having improved average glucose levels.
On the occasion of the 2011 Rare Disease Day, EDMA, the European Diagnostic Manufacturers Association, underlines the crucial role the In Vitro Diagnostic industry can play to diagnose rare diseases.
A new Associated Press-GfK poll finds that 71 percent of Americans who have tried to sign up for health coverage, or live with someone who tried, had difficulties with the insurance marketplaces. Meanwhile, some GOP leaders are seeking a policy alternative to replace the overhaul.
The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).
Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Geoffry De Gennaro Jr, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: (616) 391-3245 | Dr Geoffry De Gennaro Jr, MD 190 E Bannock St, Boise, ID 83712-6241 Ph: (208) 381-2094 |
News Archive
Abbott today announced the results of real-world use data showing that people who scan more frequently using Abbott′s FreeStyle Libre system spend less time in hypoglycaemia (low blood sugar) or hyperglycaemia (high blood sugar) while having improved average glucose levels.
On the occasion of the 2011 Rare Disease Day, EDMA, the European Diagnostic Manufacturers Association, underlines the crucial role the In Vitro Diagnostic industry can play to diagnose rare diseases.
A new Associated Press-GfK poll finds that 71 percent of Americans who have tried to sign up for health coverage, or live with someone who tried, had difficulties with the insurance marketplaces. Meanwhile, some GOP leaders are seeking a policy alternative to replace the overhaul.
The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).
Scientists searching for a therapy to stop the deadly and mostly untreatable lung disease, idiopathic pulmonary fibrosis (IPF), found a new molecular target that slows or stops the illness in preclinical laboratory tests.
› Verified 6 days ago
Dr. Micheal George Adondakis, MD Radiology Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2121 Fax: 706-596-6720 | |
Jeffrey T Seabourn, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2161 | |
Caroline D Sobota, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2161 | |
Dr. Chad Eric Sarver, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 500 W Fort St, Boise, ID 83702 Phone: 208-422-1000 | |
Mr. Jesse W Spinner, MD Radiology Medicare: Medicare Enrolled Practice Location: 1055 N Curtis Rd, Boise, ID 83706 Phone: 208-367-2121 Fax: 706-596-6720 | |
Brian Lane Mcmahan, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 190 E Bannock St, Boise, ID 83712 Phone: 208-381-2094 Fax: 208-381-1791 | |
Craig E Leymaster, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 190 E Bannock St, Boise, ID 83712 Phone: 208-381-2094 |